Novo Nordisk launches the Wegovy pill in the US, which is the first oral form of GLP-1 medication for the treatment of overweight and obesity[1]. The tablet contains semaglutide in a dose of 25 mg and is taken once a day[1]. In the OASIS 4 clinical trial, patients lost an average of 16.6% of their body weight over 64 weeks[1]. Novo Nordisk expects the pill to be available in the US in January 2026[1]. The tablet is indicated for reducing excess body weight, maintaining its reduction in the long term and reducing the risk of serious cardiovascular events[1]. Novo Nordisk is the first company to receive FDA approval for an oral GLP-1 drug to treat obesity, giving it an edge over competitor Eli Lilly, whose oral orforglipron is not expected until spring 2026[2].